KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Restructuring Costs (2009 - 2013)

Bristol Myers Squibb (BMY) reported Restructuring Costs of $33.0 million for Q1 2013, up 50.0% year-over-year from $22.0 million in Q1 2012, and down 67.96% on a QoQ basis from $103.0 million in Q4 2012.

Bristol Myers Squibb (BMY) has 5 years of Restructuring Costs data on file, last reported at $33.0 million in Q1 2013.

  • Quarterly Restructuring Costs rose 50.0% year-over-year to $33.0 million in Q1 2013, while the trailing twelve-month figure through Mar 2013 was $164.0 million (up 137.68% YoY) and the FY2012 annual result came in at $174.0 million, up 50.0% from the prior year.
  • Restructuring Costs eased to $33.0 million in Q1 2013 per BMY's latest filing, from $103.0 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $103.0 million in Q4 2012 and bottomed at $1.0 million in Q1 2011.
  • The 5-year median for Restructuring Costs is $20.0 million (2012), against an average of $27.9 million.
  • The widest annual swing landed in 2011, when Restructuring Costs sank 90.91%; it then soared 2100.0% in 2012.
  • Tracing BMY's Restructuring Costs over 5 years: stood at $35.0 million in 2009, then soared by 80.0% to $63.0 million in 2010, then sank by 61.9% to $24.0 million in 2011, then surged by 329.17% to $103.0 million in 2012, then sank by 67.96% to $33.0 million in 2013.
  • Per Business Quant, the three latest BMY Restructuring Costs figures stand at $33.0 million (Q1 2013), $103.0 million (Q4 2012), and $8.0 million (Q3 2012).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2013 33.00 Mn
Dec 31, 2012 103.00 Mn
Sep 30, 2012 8.00 Mn
Jun 30, 2012 20.00 Mn
Mar 31, 2012 22.00 Mn
Dec 31, 2011 24.00 Mn
Sep 30, 2011 8.00 Mn
Jun 30, 2011 15.00 Mn
Mar 31, 2011 1.00 Mn
Dec 31, 2010 63.00 Mn
Sep 30, 2010 15.00 Mn
Jun 30, 2010 24.00 Mn
Mar 31, 2010 11.00 Mn
Dec 31, 2009 35.00 Mn
Sep 30, 2009 54.00 Mn
Jun 30, 2009 19.00 Mn
Mar 31, 2009 19.00 Mn